



## Moxatag<sup>®</sup> (amoxicillin) – Product discontinuation

- On December 19, 2018, the [FDA announced](#) the discontinuation of Vernalis Therapeutics' [Moxatag \(amoxicillin\)](#) extended-release tablets.
  - The last batches of Moxatag will expire September 30, 2019.
- Moxatag is indicated for the treatment of tonsillitis and/or pharyngitis secondary to *Streptococcus pyogenes* in adults and pediatric patients 12 years and older.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.